Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:CARA
Raised
Post IPO Valuation

General Information

Websitecaratherapeutics.com
CategoryBioTech
Phone203-567-1500
Emailinfo@caratherapeu...
Employees

Offices

Shelton, USA
One Parrott Drive
Shelton, CT, 06484
USA

People

Board of Directors
Board of Observer

Funding

Tags

Cara Therapeutics

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Recent Milestones

Videos

Screenshots

Cara Therapeutics screenshot
Above: Cara Therapeutics
Uploaded: 4/20/10

Stock Price

Sources

  1. EDGAR [edit]
  2. Cara Therapeutics Secures $19 Million in Series C Financing. (thefreelibrary.com) [edit]
  3. Cara rounds up $15M for post-op pain drug Read more: Cara rounds up $15M for post-op pain drug (fiercebiotech.com) [edit]
  4. Pain Therapy Developer Issues IPO, Raises $55 Million (sciencebusiness.technewslit.com) [edit]
Edit This Page
Last Edited 3/13/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy